An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura

British Journal of Haematology

Volumn 135, Issue 4, 2006, Pages 547-553

  Newland, Adrian ^a,i   Caulier, Marie T ^b   Kappers Klunne, Mies ^c   Schipperus, Martin R ^d   Lefrere, Francois ^e   Zwaginga, Jaap J ^f   Christal, Jenny ^g   Chen, Chien Feng ^h   Nichol, Janet L ^h  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d HagaZiekenhuis ^*  (Netherlands)

^e HÔPITAL NECKER ENFANTS MALADES   (France)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^g AMGEN LTD   (United Kingdom)

^h AMGEN INC   (United States)

ⁱ ROYAL LONDON HOSPITAL   (United Kingdom)

Author keywords

AMG 531; Immune thrombocytopenia; Thrombopoietin

Indexed keywords

AMG 531; ANTIBODY; LACTATE DEHYDROGENASE; PREDNISONE; THROMBOPOIESIS STIMULATING PEPTIBODY; THROMBOPOIETIN; THROMBOPOIETIN ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ARTHRALGIA; ARTICLE; BACKACHE; BREAST TUMOR; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONTUSION; DIARRHEA; DOSE RESPONSE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECCHYMOSIS; EPISTAXIS; FATALITY; FATIGUE; FEMALE; HEADACHE; HEMATOMA; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOASSAY; INJECTION SITE BLEEDING; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; MENORRHAGIA; MULTICENTER STUDY; MUSCULOSKELETAL PAIN; OPEN STUDY; ORAL BLEEDING; PERIPHERAL EDEMA; PETECHIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RHINOPHARYNGITIS; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; CARRIER PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT SELECTION; PLATELET COUNT; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECEPTORS, FC; RECOMBINANT FUSION PROTEINS; THROMBOPOIESIS; THROMBOPOIETIN; TREATMENT OUTCOME;

EID: 33750051618     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2006.06339.x     Document Type: Article

References (23)

1. Aledort, L.M., Hayward, C.P., Chen, M.G., Nichol, J.L. & Bussel, J. (2004) Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts, endogenous thrombopoietin, and circulating antithrombopoietin antibodies. American Journal of Hematology, 76, 205-213.
2. Ballem, P.J., Segal, G.M., Stratton, J.R., Gernsheimer, T., Adamson, J.W. & Slichter S.J. (1987) Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenia purpura. Evidence of both impaired platelet production and increased platelet clearance. Journal of Clinical Investigation, 80, 33-40.
3. Basser, R.L., O'Flaherty, E., Green, M., Edmonds, M., Nichol, J., Menchaca, D.M., Cohen, B. & Begley, C.G. (2002) Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. Blood, 99, 2599-2602.
4. Berchtold, P. & McMillan, R. (1989) Therapy of chronic idiopathic thrombocytopenic purpura in adults. Blood, 74, 2309-2317.
5. Bottiger, L.E. & Westerholm, B. (1972) Thrombocytopenia. I. Incidence and aetiology. Acta Medica Scandinavica, 191, 535-540.
6. Broudy, V.C. & Lin, N.L. (2004) AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl. Cytokine, 25, 52-60.
7. Debili, N., Wendling, F., Katz, A., Guichard, J., Breton-Gorius, J., Hunt, P. & Vainchenker, W. (1995) The Mpl-ligand of thrombopoietin or megakaryocyte growth and differentiative factor has both direct proliferative and differentiative activities on human megakaryocyte progenitors. Blood, 86, 2516-2525.
8. George, J.N., El Harake, M.A. & Aster, R.H. (1995) Thrombocytopenia due to enhanced platelet destruction by immunologic mechanisms. In: Williams Hematology (ed. by E. Beutler, M.A. Lichtman, B.S. Coller, J.J. Kipps & U. Seligsohn), 6th edn, pp. 1315-1355. McGraw-Hill, New York.
9. George, J.N., Woolf, S.H., Raskob, G.E., Wasser, J.S., Aledort, L.M., Ballem, P.J., Blanchette, V.S., Bussel, J.B., Cines, D.B., Kelton, J.G., Lichtin, A.E., McMillan, R., Okerbloom, J.A., Regan, D.H. & Warrier, I. (1996) Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood, 88, 3-40.
10. Heyns, A.D., Lotter, M.G., Badenhorst, P.N., de Kock, F., Pieters, H., Herbst, C., van Reenen, O.R., Kotze, H. & Minnaar, P.C. (1982) Kinetics and sites of destruction of 111 Indium-oxine-labeled platelets in idiopathic thrombocytopenic purpura: a quantitative study. American Journal of Hematology, 12, 167-177.
11. Heyns A. D., Badenhorst, P.N., Lotter, M.G., Pieters, H., Wessels, P. & Kotze, H.F. (1986) Platelet turnover and kinetics in immune thrombocytopenic purpura: results with autologous 111 ln-labeled platelets and homologous 51 Cr-labeled platelets differ. Blood, 67, 86-92.
12. Kelton, J.G. & Gibbons, S. (1982) Autoimmune platelet destruction: idiopathic thrombocytopenic purpura. Seminars in Thrombosis and Hemostasis, 8, 83-104.
13. Li, J., Yang, C., Xia, Y., Bertino, A., Glaspy, J., Roberts, M. & Kuter, D.J. (2001) Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood, 98, 3241-3248.
14. McMillan, R. (1981) Chronic idiopathic thrombocytopenic purpura. New England Journal of Medicine, 304, 1135-1147.
15. McMillan, R. (1997) Therapy for adults with refractory chronic immune thrombocytopenic purpura. Annals of Internal Medicine, 126, 307-314.
16. Methia, N., Louache, F., Vainchenker, W. & Wendling, F. (1993) Oligodeoxynucleotides antisense to the proto-oncogene c-mpl specifically inhibit in vitro megakaryocytopoiesis. Blood, 82, 1395-1401.
17. Nichol, J.L. (1998) The Mpl ligand and platelet homeostasis. Acta Paediatrica. Supplement, 424, 7-15.
18. Provan, D. & Newland, A.C. (2002) Fifty years of idiopathic thrombocytopenic purpura: management of refractory ITP in adults. British Journal of Haematology, 118, 933-944.
19. Provan, D., Newland, A.C., Norfolk, D., Bolton-Maggs, P., Lilleyman, J., Greer, I., May, A., Murphy, M., Ouwehand W. & Watson S. (2003) Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. British Journal of Haematology, 120, 574-596.
20. Sheridan, W.P., Choi, E., Toombs, C.F., Nichol, J., Fanucchi, M.W., Basser, R.I. (1997) Biology of thrombopoiesis and the role of the Mpl ligand in the production and function of platelets. Platelets, 8, 319-332.
21. Siegel, R.S., Rae, J.L., Barth, S., Coleman, R.E., Reba, R.C., Kurlander, R. & Rosse, W.F. (1989) Platelet survival and turnover: important factors in predicting response to splenectomy in immune thrombocytopenic purpura. American Journal of Hematology, 30, 206-212.
22. Stoll, D., Cines, D.B., Aster, R.H. & Murphy, S. (1985) Platelet kinetics in patients with idiopathic thrombocytopenic purpura and moderate thrombocytopenia. Blood, 65, 584-588.
23. Wang, B., Nichol, J.L. & Sullivan, J.T. (2004) Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clinical Pharmacology and Therapeutics, 76, 628-638.